Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.
We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.
GRAIL is headquartered in Sunnyvale, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
For more information, please visit grail.com.
Community Guidelines: https://bit.ly/3xigb24
Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.
Freenome is a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests that can identify cancer in its earliest, most treatable stages.
We operate an expansive, CLIA-certified clinical and research lab in our headquarters in Brisbane, CA. Our development of SimpleScreen CRC (approved by the FDA in July 2026) for colorectal cancer screening, SimpleScreen Lung (launched as a laboratory-developed test in October 2026) and a pipeline of tests for additional indications is designed to increase cancer screening participation among millions of at-risk individuals.
Freenome went public in July 2026, entering Nasdaq under the ticker symbol “FRNM” and raising gross proceeds of $310 million. The company has a licensing agreement with Abbott to lead the U.S. commercialization of SimpleScreen CRC, as well as a strategic collaboration partnership with Roche for R&D and ex-U.S. commercialization of our screening technology.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross-functional collaboration, and whose work makes a significant impact on the company and their career.